AzTrials
AzTrials

Idiopathic Restless Legs SyndromePhase 3RLSNCT00806026

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

A Phase 3 study testing pramipexol and Pregabalin in people with Idiopathic Restless Legs Syndrome, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 110 sites in 9 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Idiopathic Restless Legs Syndrome
What is being tested?
pramipexol and Pregabalin
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
731 participants
Where
110 sitesin 9 countries
Study dates
Dec 2008to May 2011
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • idiopathic RLS with the presence of all four clinical manifestations of RLS
  • RLS symptoms occur predominantly in the evening
  • RLS history at least 6 months
  • IRLS => 15 at the beginning and the end of placebo run-in
  • Have =>15 nights with RLS symptoms in the month prior to screening

Who cannot join

  • Any secondary RLS
  • Current augmentation due to RLS treatment
  • Placebo responders identified during the placebo run-in

Trial locations and contacts

110 sites in 9 countries.

110 sites in 9 countries

United States42 sites
  • Pfizer Investigational Site

    Atlanta, Georgia, 30342

  • Pfizer Investigational Site

    Aurora, Colorado, 80012

  • Pfizer Investigational Site

    Austin, Texas, 78731

  • Pfizer Investigational Site

    Baton Rouge, Louisiana, 70808

  • Pfizer Investigational Site

    Birmingham, Alabama, 35209

  • Pfizer Investigational Site

    Boca Raton, Florida, 33486

  • Pfizer Investigational Site

    Chevy Chase, Maryland, 20815

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45219

  • Pfizer Investigational Site

    Columbus, Ohio, 43210

  • Pfizer Investigational Site

    Dallas, Texas, 75231

  • Pfizer Investigational Site

    Glendale, Arizona, 85308

  • Pfizer Investigational Site

    Hallandale, Florida, 33009

  • Pfizer Investigational Site

    Houston, Texas, 77063

  • Pfizer Investigational Site

    Jasper, Alabama, 35501

  • Pfizer Investigational Site

    Lafayette Hill, Pennsylvania, 19444

  • Pfizer Investigational Site

    Little Rock, Arkansas, 72205

  • Pfizer Investigational Site

    Little Rock, Arkansas, 72211

  • Pfizer Investigational Site

    Louisville, Kentucky, 40217

  • Pfizer Investigational Site

    Miami, Florida, 33143

  • Pfizer Investigational Site

    Minneapolis, Minnesota, 55415

  • Pfizer Investigational Site

    New York, New York, 10019

  • Pfizer Investigational Site

    Newton, Massachusetts, 02459

  • Pfizer Investigational Site

    Northridge, California, 91325

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73112

  • Pfizer Investigational Site

    Overland Park, Kansas, 66212

  • Pfizer Investigational Site

    Pembroke Pines, Florida, 33026

  • Pfizer Investigational Site

    Phoenix, Arizona, 85032

  • Pfizer Investigational Site

    Phoenix, Arizona, 85050

  • Pfizer Investigational Site

    Plano, Texas, 75093

  • Pfizer Investigational Site

    Princeton, New Jersey, 08540

  • Pfizer Investigational Site

    Redondo Beach, California, 90277

  • Pfizer Investigational Site

    Salisbury, North Carolina, 28144-0000

  • Pfizer Investigational Site

    Salisbury, North Carolina, 28144

  • Pfizer Investigational Site

    San Diego, California, 92103

  • Pfizer Investigational Site

    San Diego, California, 92121

  • Pfizer Investigational Site

    Santa Monica, California, 90404

  • Pfizer Investigational Site

    South Miami, Florida, 33143

  • Pfizer Investigational Site

    Southfield, Michigan, 48034

  • Pfizer Investigational Site

    Torrance, California, 90502

  • Pfizer Investigational Site

    Tuscaloosa, Alabama, 35406

  • Pfizer Investigational Site

    Walla Walla, Washington, 99362

  • Pfizer Investigational Site

    Winston-Salem, North Carolina, 27103

Other trials in United States

Germany37 sites
  • Pfizer Investigational Site

    Achim, 28832

  • Pfizer Investigational Site

    Bad Saarow, 15526

  • Pfizer Investigational Site

    Berlin, 10117

  • Pfizer Investigational Site

    Berlin, 10245

  • Pfizer Investigational Site

    Berlin, 10365

  • Pfizer Investigational Site

    Berlin, 10437

  • Pfizer Investigational Site

    Berlin, 10629

  • Pfizer Investigational Site

    Berlin, 10969

  • Pfizer Investigational Site

    Berlin, 12163

  • Pfizer Investigational Site

    Berlin, 12683

  • Pfizer Investigational Site

    Berlin, 13156

  • Pfizer Investigational Site

    Bochum, 44787

  • Pfizer Investigational Site

    Bochum, 44805

  • Pfizer Investigational Site

    Bremen, 28325

  • Pfizer Investigational Site

    Dortmund, 44229

  • Pfizer Investigational Site

    Dresden, 01307

  • Pfizer Investigational Site

    Freiburg im Breisgau, 79106

  • Pfizer Investigational Site

    Gelsenkirchen, 45879

  • Pfizer Investigational Site

    Halle, 06118

  • Pfizer Investigational Site

    Hamm, 59065

  • Pfizer Investigational Site

    Jena, 07743

  • Pfizer Investigational Site

    Jülich, 52428

  • Pfizer Investigational Site

    Kassel, 34128

  • Pfizer Investigational Site

    Kassel, 34131

  • Pfizer Investigational Site

    Köthen, 06366

  • Pfizer Investigational Site

    Leipzig, 04107

  • Pfizer Investigational Site

    Marburg, 35039

  • Pfizer Investigational Site

    München, 80331

  • Pfizer Investigational Site

    Oldenburg, 26122

  • Pfizer Investigational Site

    Prien am Chiemsee, 83209

  • Pfizer Investigational Site

    Schwerin, 19053

  • Pfizer Investigational Site

    Siegen, 57072

  • Pfizer Investigational Site

    Ulm, 89073

  • Pfizer Investigational Site

    Ulm, 89081

  • Pfizer Investigational Site

    Unterhaching, 82008

  • Pfizer Investigational Site

    Westerstede, 26655

  • Pfizer Investigational Site

    Würzburg, 97070

Other trials in Germany

Sweden10 sites
  • Pfizer Investigational Site

    Avesta, 77482

  • Pfizer Investigational Site

    Avesta, SE-774 82

  • Pfizer Investigational Site

    Gothenburg, 40530

  • Pfizer Investigational Site

    Gothenburg, 413 45

  • Pfizer Investigational Site

    Örebro, 701 85

  • Pfizer Investigational Site

    Örebro, 70185

  • Pfizer Investigational Site

    Skövde, 541 85

  • Pfizer Investigational Site

    Skövde, 54185

  • Pfizer Investigational Site

    Skövde, SE-541 85

  • Pfizer Investigational Site

    Stockholm, 11245

Other trials in Sweden

Italy6 sites
  • Pfizer Investigational Site

    Pavia, 27100

  • Pfizer Investigational Site

    Pisa, 56126

  • Pfizer Investigational Site

    Rome, 00163

  • Pfizer Investigational Site

    Rome, 00185

  • Pfizer Investigational Site

    Troina, 94018

  • Pfizer Investigational Site

    Troina(EN), 94018

Other trials in Italy

Spain5 sites
  • Pfizer Investigational Site

    Barcelona, Cataluña/Spain, 08003

  • Pfizer Investigational Site

    Barcelona, 08035

  • Pfizer Investigational Site

    Barcelona, 08036

  • Pfizer Investigational Site

    Granada, 18014

  • Pfizer Investigational Site

    Madrid, 28036

Other trials in Spain

Finland4 sites
  • Pfizer Investigational Site

    Helsinki, 00420

  • Pfizer Investigational Site

    Kuopio, 70210

  • Pfizer Investigational Site

    Tampere, 33520

  • Pfizer Investigational Site

    Turku, 20520

Other trials in Finland

Austria3 sites
  • Pfizer Investigational Site

    Innsbruck, A-6020

  • Pfizer Investigational Site

    Linz, A-4021

  • Pfizer Investigational Site

    Vienna, 1090

Other trials in Austria

Netherlands2 sites
  • Pfizer Investigational Site

    Ede, 6716 RP

  • Pfizer Investigational Site

    Zwolle, 8025 BV

Other trials in Netherlands

United Kingdom1 site
  • Pfizer Investigational Site

    Reading Berks, RG2 0TG

Other trials in United Kingdom

About this study

Official title: Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome

This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.

Being tested
placebo and pregabalin, pramipexol, Pregabalin
Keywords
RLS

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • placebo and pregabalinDrug

    Also called Lyrica

    following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.

  • pramipexolDrug

    Also called Mirapex

    following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.

  • pramipexolDrug

    Also called Mirapex

    following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.

  • PregabalinDrug

    Also called Lyrica

    pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months

  • pramipexolDrug

    Also called Mirapex

    pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months

  • pramipexolDrug

    Also called Mirapex

    pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months

Study groups in NCT00806026
Study groupRoleWhat they receive
PBO/PGB 300 mgExperimentalNot described
Receives: Drug: placebo and pregabalin
PBO/PPX 0.25 mgActive comparatorNot described
Receives: Drug: pramipexol
PBO/PPX 0.5 mgActive comparatorNot described
Receives: Drug: pramipexol
PGB 300 mgExperimentalNot described
Receives: Drug: Pregabalin
PPX 0.25 mgActive comparatorNot described
Receives: Drug: pramipexol
PPX 0.5 mgActive comparatorNot described
Receives: Drug: pramipexol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Restless Legs Syndrome (RLS) Symptom Severity

    International Restless Legs Syndrome Study Group Rating Scale (IRLS) is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.

    Measured: Baseline

  2. Change From Baseline in the RLS Symptom Severity at Week 12

    IRLS is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.

    Measured: Baseline, Week 12

  3. Percentage of Participants Responding to Treatment at Week 12

    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Responders were defined as participants who report CGI-I score of "very much improved" or "much improved".

    Measured: Week 12

  4. Percentage of Participants With Augmentation

    Augmentation was worsening of RLS symptoms, attributable to a specific long-term therapeutic intervention for RLS. Percentage of participants with augmentation was evaluated by centralized evaluation board using a set of assessment criteria for potential augmentation which included structured interview for diagnosis of augmentation during RLS treatment (SIDA-RLS), augmentation severity rating scale (ASRS), clinical judgment. ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.

    Measured: Baseline up to Week 52

Secondary outcomes (18)
  1. Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO)

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.

    Measured: Baseline

  2. Change From Baseline in SSQ: Subjective WASO at Week 12

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.

    Measured: Baseline, Week 12

  3. Subjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 12

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Latency subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Latency subscale score ranges from 0-840 minutes. Lower value indicates better sleep.

    Measured: Week 12

  4. Subjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 12

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Hours of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Hours of sleep subscale score ranges from 0-16 hours. Higher value indicates better sleep.

    Measured: Week 12

  5. Subjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 12

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Number of awakenings subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Number of awakenings subscale score ranges from 0-30. Lower value indicates better sleep.

    Measured: Week 12

  6. Subjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 12

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Quality of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Quality of sleep subscale score ranges from 0-100. Higher score indicates better quality of sleep.

    Measured: Week 12

  7. RLS-Next Day Impact (RLS-NDI)

    The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.

    Measured: Baseline

  8. Change From Baseline in RLS-NDI at Week 12

    The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.

    Measured: Baseline, Week 12

  9. Limb Pain-Visual Analog Scale (Limb Pain-VAS)

    100 millimeter (mm) line (Visual Analog Scale) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.

    Measured: Baseline

  10. Change From Baseline in Limb Pain-VAS at Week 12

    100 mm line (VAS) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain. Change = observation mean minus baseline mean.

    Measured: Baseline, Week 12

  11. Severity of Augmentation Symptoms at Week 12

    ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.

    Measured: Week 12

  12. Clinical Global Impressions-Severity (CGI-S) at Week 12

    CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal-not ill at all) to 7 (among the most extremely ill participants). Higher score = more affected.

    Measured: Week 12

  13. Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 12

    MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Sleep adequacy data was reported at week 12 and not for first 12 weeks (average). Subscale scores range: 0-100; exception quantity of sleep (range 0-24 hours). With exception of sleep quantity and sleep adequacy, higher scores reflect poorer sleep outcomes.

    Measured: Week 12

  14. Number of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 12

    MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/ headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Optimal sleep subscale scores range: 0-1; Optimal sleep = 1 if 'Average hours sleep' = 7 or 8, is 0 if 'Average hours sleep' is non-missing and less than 7, and is missing if 'Average hours sleep' is missing. Higher scores reflect better sleep outcomes.

    Measured: Week 12

  15. Profile of Mood State (POMS) at Week 12

    POMS are participant-rated instrument comprising 6 sub-scales (tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment) and each subscale comprising 5 items, on 'How you feel right now?' (Scale: 0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for vigor-activity. A total score is obtained for each scale. The range of total score is 0 - 100, with higher score indicating more mood disturbance.

    Measured: Week 12

  16. Restless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 12

    RLS QoL: Participant rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life.

    Measured: Week 12

  17. Medical Outcomes Study-Short Form 36 (SF-36) at Week 12

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health); 2 summary scores (physical and mental component); and self evaluated change in health status (summary of health status). The score for subscale scores and 2 summary score is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Summary of health status is a 5-point Likert scale ranging from "0=much worse now" to "4=much better now". Higher subscale and summary score reflect better health status.

    Measured: Week 12

  18. Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) at Week 12

    WPAI: 6 question participant rated questionnaire to determine degree to which SHP affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 10 (completely affected/impaired). WPAI outcomes expressed as impairment percentages with higher numbers indicating greater impairment and less productivity.

    Measured: Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Dec 2008 (estimated)
  2. Study startDec 2008
  3. Primary completionMay 2011
  4. Study completionMay 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
731 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00806026
Sponsor's protocol ID
A0081186
Acronym
RLS
Status last verified
Aug 2012
First submitted
9 Dec 2008
Last updated
26 Jan 2021
Data monitoring committee
Yes

Publications

  • Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014 Feb 13;370(7):621-31. doi: 10.1056/NEJMoa1303646.

    PubMed 24521108

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing pramipexol and Pregabalin in people with Idiopathic Restless Legs Syndrome, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 110 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 110 sites in United States, Germany, Sweden, Italy, Spain and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Sep 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Restless Legs Syndrome (RLS) Symptom Severity (time frame: Baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00806026, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in